Melanoma: all 3,073 studies
Page 25 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingNCT01364051Phase 1
- Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in MelanomaCompletedNCT01363206Phase 2
- Melanoma Risk Assessment & Tailored InterventionCompletedNCT01356771Not applicable
- Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney CancerWithdrawnNCT01355562Phase 2
- THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseCompletedNCT01355120Phase 2
- A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsCompletedNCT01351103Phase 1
- Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
- NAM-Trial: Multiferon in Malignant MelanomaCompletedNCT01341158Phase 2
- Open-Label Study of TPI 287 for Patients With Metastatic MelanomaWithdrawnNCT01340729Phase 1/2
- Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic MelanomaCompletedNCT01339663Phase 1
- Influence of Oral Treatment with Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas with Proton Beam TherapyCompletedNCT01338389Not applicable
- Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting BeadsTerminatedNCT01336985Phase 1
- Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma PatientsCompletedNCT01336270
- Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma PatientsStatus unknownNCT01331915Phase 1/2
- Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal MelanomaWithdrawnNCT01328106Phase 2
- Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
- Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and ControlsWithdrawnNCT01312506
- Liver Transplantation and Uveal Malignant MelanomaCompletedNCT01311466Not applicable
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaActive, not recruitingNCT01303341Phase 1
- Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT01302496Phase 2
- Nuclear and Near-Infrared (NIR) Imaging in MelanomaCompletedNCT01295931Phase 1
- Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
- IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced MelanomaCompletedNCT01288963
- Role of SLURP-1 in Melanoma and Melanoma Stem CellsStatus unknownNCT01281722
- Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitTerminatedNCT01280565Phase 3
- Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant MelanomaCompletedNCT01278940Phase 1/2
- Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol GelTerminatedNCT01272609Phase 3
- PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing StudyActive, not recruitingNCT01266096Not applicable
- MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma PatientsTerminatedNCT01264874Phase 3
- Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of MelanomaCompletedNCT01264731Phase 1
- Nordic Adjuvant IFN Melanoma TrialCompletedNCT01259934Phase 3
- Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal MelanomaCompletedNCT01253759
- Intratumoral Application of L19IL2 in Patients With Malignant MelanomaCompletedNCT01253096Phase 2
- Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant MelanomaCompletedNCT01247623Phase 1/2
- Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCompletedNCT01245556Phase 1
- Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid TumorsCompletedNCT01239134Phase 1
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation TherapyActive, not recruitingNCT01223248Phase 3
- Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the EyeStatus unknownNCT01217398Phase 2
- RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by SurgeryWithdrawnNCT01216787Phase 2
- Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1CompletedNCT01216696Phase 2
- Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic MelanomaTerminatedNCT01216657Phase 2
- Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic MelanomaTerminatedNCT01216436Phase 1
- Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV MelanomaCompletedNCT01213732Phase 1
- A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic MelanomaTerminatedNCT01212276Phase 1
- IMCgp100 in Advanced Unresectable MelanomaCompletedNCT01209676Early Phase 1
- Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib TosylateCompletedNCT01209299
- A Study of PNT2258 in Patients With Advanced Solid TumorsCompletedNCT01191775Phase 1
- Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for MelanomaCompletedNCT01191294Not applicable
- Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic MelanomaTerminatedNCT01191034Phase 1/2
- IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV MelanomaCompletedNCT01189383Phase 1/2
- Trial of Surgical Excision Margins in Thick Primary MelanomaCompletedNCT01183936Not applicable
- Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedNCT01176474Phase 1
- Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558CompletedNCT01176461Phase 1
- Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Status unknownNCT01168050Phase 2
- Early Diagnosis of Malignant Transformation of Pigmentary Skin LesionsStatus unknownNCT01167998
- Study of a DNA Immunotherapy to Treat MelanomaTerminatedNCT01138410Phase 1/2
- Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour PatientsCompletedNCT01134250Phase 1/2
- Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
- Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb InfusionCompletedNCT01127594Phase 1
- Safety Study of Human IgM (MORAb-028) to Treat Metastatic MelanomaTerminatedNCT01123304Phase 1
- NIR-Guided Sentinel Lymph Node Mapping in MelanomaCompletedNCT01121718Phase 1
- Using High Resolution Function Imaging To Detect Melanoma and Dysplastic NeviCompletedNCT01118832
- Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic MelanomaTerminatedNCT01106235Phase 1
- Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaCompletedNCT01103635Phase 1
- Study of Nilotinib in Metastatic Melanoma With KIT AberrationsCompletedNCT01099514Phase 2
- Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDHStatus unknownNCT01092585Phase 2
- Use of Fiber-optic Probe for Non-invasive Diagnosis of Melanoma and Assessment of Impact of Ultraviolet (UV) Exposure on SkinTerminatedNCT01085396
- A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg)TerminatedNCT01082887Phase 1/2
- Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph NodesStatus unknownNCT01082198Phase 1/2
- An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaCompletedNCT01078961Phase 1
- Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 TherapyTerminatedNCT01068470
- A Phase I Study of TPI 287 - Temozolomide Combination in MelanomaTerminatedNCT01067066Phase 1
- A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT01066390Phase 1
- Panobinostat (LBH589) in Patients With Metastatic MelanomaCompletedNCT01065467Phase 1
- Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV CancerCompletedNCT01065441Phase 1/2
- Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic MelanomaTerminatedNCT01055522Phase 2
- Safety Study of a Liposomal Vaccine to Treat Malignant MelanomaCompletedNCT01052142Phase 1
- Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous SystemCompletedNCT01048554Phase 2
- Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic MelanomaTerminatedNCT01045915Phase 1
- Study of Weekly LOC-paclitaxel Injection for MelanomaTerminatedNCT01039844Phase 1
- Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal MelanomaCompletedNCT01034787Phase 2
- Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients SettingCompletedNCT01034696
- Rituximab in Metastatic MelanomaTerminatedNCT01032122Phase 1
- Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With MelanomaTerminatedNCT01026051Phase 2
- A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell CancerCompletedNCT01021059Phase 1
- Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II MelanomaStatus unknownNCT01018004
- Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial LesionsCompletedNCT01017185Phase 1
- Stage IV Surgery Versus Best Medical TherapyTerminatedNCT01013623Phase 3
- Dose Escalation Study of MLN4924 in Adults With MelanomaCompletedNCT01011530Phase 1
- A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV MelanomaCompletedNCT01009775Phase 2
- Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)CompletedNCT01009177Phase 2
- Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100CompletedNCT01008527Phase 1
- Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic MelanomaNo longer availableNCT01005537
- Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant MelanomaCompletedNCT01005472Phase 1
- Interstitial Fluid Pressure (IFP) Pilot Study in Melanoma PatientsWithdrawnNCT01003626Not applicable
- The Identification of Novel Prognostic Markers in MelanomaStatus unknownNCT01002560
- Ultraviolet Light Exposure and Immunosuppression in Cutaneous MelanomaTerminatedNCT00996827
- Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant MelanomaTerminatedNCT00991991
- SentoClone® Compared to Reference Treatment in Advanced Malignant MelanomaStatus unknownNCT00991250Phase 2